KCT0007375进行中（未招募）未知
The Effect of Intravitreal Aflibercept for Neovascular membrane, Pigment Epithelial Detachment and/or Subretinal Fluid Secondary to Type 1 Choroidal Neovascularization: Quantitative analysis based on OCT and OCT Angiography
Kyung Hee University Hospital0 个研究点目标入组 40 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 40
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional Study
入排标准
- 年龄范围
- 50(Year) 至 o Limit（—）
- 性别
- All
入选标准
- •1. Active choroidal neovascularization confirmed by optical coherence tomography angiography or fluorescein angiography and indocyanine green angiography
- •- When the subretinal fluid accompanied by irregular elevation of the retinal pigment epithelium is confirmed by optical coherence tomography
- •- In cases where choroidal neovascularization is observed in optical coherence tomography angiography or fluorescein angiography and indocyanine green angiography
- •2. Male or female patients over 50 years of age who have signed the informed consent form
- •3. In the absence of active ocular or systemic disease
- •4. Patients who understand the process of this clinical trial, are cooperative, and are judged to be able to participate by the end of the clinical trial
排除标准
- •1. Pregnant or lactating women
- •2. Patients participating in other clinical trials
- •3. If patient have received anti-vascular endothelial growth factor treatment within the last 90 days
- •4. If patient have received photodynamic therapy 3 times or more or within the last 90 days
- •5. Clinically prominent diabetic retinopathy or diabetic macular edema
- •6. Clinically significant scar or atrophy of the fovea
- •7. Active Intraocular Inflammation or Infection
- •8. In case of hypersensitivity to Afilbercept and other ingredients in Eylea
- •9. History of intravitreal triamcinolone injection treatment within the last 3 months
- •10. History of intravitreal dexamethasone injection treatment within the last 6 months
- •11. History of use of inhaled or sprayed or dermal steroids for more than 30 consecutive days within the last 3 months
- •12. History of eye surgery, including vitrectomy, glaucoma surgery, and scleral buckling within the last 3 months (Excluding simple cataract surgery and vision correction surgery)
- •13. Diagnosed with retinal vascular disease other than age-related macular degeneration
- •14. Cerebrovascular disease, myocardial infarction diagnosed within the one year
研究者
相似试验
已完成
4 期
The study of Intravitreal aflibercept with treat and extend regimen for macular edema with branch retinal vein occlusion (BRVO)Branch retinal vein occlusionJPRN-UMIN000023200Department of Ophthalmology, Akita University50
已完成
不适用
Efficacy evaluation of intravitreal aflibercept for polypoidal choroidal vasculopathyJPRN-UMIN000010461Yokohama City University Medical Center30
已完成
3 期
The efficacy of intravitreal aflibercept given in a ‘treat and extend’ regime in the treatment of cystoid macular oedema secondary to central retinal vein occlusion.central retinal vein occlusion (CRVO).cystoid macular oedemaEye - Diseases / disorders of the eyeACTRN12615000417583Centre for Eye Research Australia20
已完成
不适用
Effect of Intravitreal Aflibercept Injection on Microaneurysm in Patients with Diabetic Macular EdemaJPRN-UMIN000018315Department of Ophthalmology, Mie University30
进行中（未招募）
1 期
The Effect of Intravitreal Aflibercept on Ocular Perfusion – a Pilot StudyExudative AMDMedDRA version: 19.1Level: LLTClassification code 10025411Term: Macular degeneration senileSystem Organ Class: 100000004853EUCTR2016-004608-78-ATKepler University Hospital, Institute of Ophthalmology